The PMCF Plan is one of the most frequently questioned documents in EU MDR Notified Body reviews. Despite clear requirements in EU MDR Annex XIV Part B and MDCG 2020-7, a large proportion of PMCF Plans in circulation do not satisfy what reviewers expect. The gaps tend to follow predictable patterns — understanding them in advance is the most efficient way to avoid them.
Confusing the PMCF Plan with the PMCF Evaluation Report
The PMCF Plan and the PMCF Evaluation Report are distinct documents with different purposes and review cycles. The Plan specifies what PMCF activities will be conducted, why, by what methods, and to what endpoints. The Evaluation Report summarises the findings from those activities and feeds back into the CER. A document that blends both purposes — or one that presents findings from completed activities where a plan for ongoing activities is required — will be flagged immediately.
Methods described but not justified
Stating that PMCF will be conducted via "literature review, registry participation, and post-market clinical follow-up survey" is not a PMCF Plan — it is a list of methods. The MDR requirement, reinforced by MDCG 2020-7, is that the rationale for each method must be documented: why is this method appropriate for this device and this residual risk? What will it measure that the initial clinical evaluation did not address?
A compliant PMCF Plan justifies each method against the specific gaps or uncertainties identified in the clinical evaluation. Where a method is not justified against a specific evidence need, reviewers will ask why it was selected and what it is expected to contribute.
No endpoints, evaluation criteria, or success thresholds
A PMCF activity without defined endpoints is not evaluable. The Plan should specify what will be measured — clinical outcomes, device performance metrics, adverse event rates, patient-reported outcomes — how it will be measured, and what threshold of results would confirm or challenge the benefit-risk conclusions in the CER. Without this, the PMCF Evaluation Report cannot be written in a way that is traceable to the original evaluation.
No connection to residual risks
The clearest way to justify a PMCF activity is to connect it to a specific residual risk or benefit-risk uncertainty identified in the risk management file and CER. If a device carries a residual risk of a rare but serious complication, the PMCF Plan should include an activity that would detect and quantify that complication in real-world use. Where the PMCF Plan bears no visible relationship to the residual risks documented elsewhere in the technical file, it reads as a compliance exercise rather than a genuine evidence-generation plan — and reviewers treat it accordingly.
No timeline, responsibility matrix, or update triggers
EU MDR requires that PMCF is planned, not just described. A compliant PMCF Plan includes a timeline for each activity, a named responsibility for execution, and clear criteria for when the Plan should be reviewed and updated. These are administrative requirements but they matter: a Plan without a timeline cannot be assessed for compliance, and a Plan without update criteria has no mechanism for responding to new evidence.
Generic literature search methodology
Where literature review is included as a PMCF method, the search methodology should be device-specific: relevant databases, search terms tied to the device's intended purpose and clinical context, inclusion and exclusion criteria, and an appraisal framework for the evidence retrieved. A Plan that specifies "PubMed and Embase searches on relevant topics" is not sufficient. The Notified Body will want to know that the literature review methodology is capable of identifying the evidence needed to assess the specific benefit-risk uncertainties the PMCF is designed to address.
Addressing these gaps
Most PMCF Plan deficiencies can be addressed in a structured revision rather than a full rewrite. The most efficient starting point is a gap assessment that maps the existing document against MDCG 2020-7 and the specific clinical evaluation gaps it is supposed to address. This identifies which sections need substantive revision and which need only clarification, allowing effort to be focused on the highest-risk gaps first.